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The novel coronavirus severe acute respi-
ratory syndrome coronavirus 2 
(SARS- CoV-2) causes COVID-19 and has 
spread rapidly. COVID-19 was declared a 
pandemic by the WHO on 12 March 
2020. Robust, population- based data 
describing COVID-19 during pregnancy 
and the neonatal period are critical to 
understand and manage this global threat 
in these groups.
There are three key ways that 
SARS- CoV-2 could affect neonates:
1. Vertical transmission of SARS- CoV-2 
from mother to infant, which may lead 
to neonatal COVID-19.
2. Horizontal transmission of SARS- 
CoV-2 in the neonatal period, poten-
tially leading to neonatal COVID-19; 
this may occur from family contacts or 
nosocomial transmission in healthcare 
settings, such as neonatal units.
3. Indirect effects on the newborn fol-
lowing maternal COVID-19 that im-
pact pregnancy or labour and birth, 
leading to complications, such as 
preterm birth. This will include situa-
tions where the neonate is affected by, 
but does not contract, SARS- CoV-2.
The impact of COVID-19 on 
neonates, as well as the importance of 
these different potential mechanisms 
of exposure, remains unclear. Vertical 
transmission of SARS- CoV-2 has yet 
to be definitively established; neonatal 
infection with the virus has been 
detected in the first days after birth to 
mothers with COVID-191; however, 
this could represent early horizontal 
transmission. Support for vertical trans-
mission comes from serological testing 
following maternal COVID-19, which 
found SARS- CoV-2 IgM in umbilical 
cord blood2; however, SARS- CoV-2 viral 
RNA was not detected in these newborns, 
and the validity of current serological 
tests remains to be established.3 Never-
theless, neonates can be symptomatic 
with COVID-19 regardless of the mech-
anism of transmission. Although initial 
data indicated that the disease was less 
severe in children,4 approximately 10% 
of neonates and infants with COVID-19 
develop severe or critical disease, a 
higher proportion than that in any other 
paediatric age group.5 The wider impact 
of maternal COVID-19 on the offspring 
is even less well understood. Several 
hundred cases of COVID-19 and asymp-
tomatic SARS- CoV-2 infection6 have 
been reported in pregnancy, and while 
the majority of newborns were asymp-
tomatic, cases of preterm birth and one 
neonatal death (a preterm infant negative 
for SARS- CoV-2) have been reported.7 
Higher rates of stillbirth and preterm 
delivery were found in women affected 
by the 2009/H1N1 influenza pandemic.8 
A similar pattern, if seen in SARS- CoV-2, 
may result in higher requirements for 
neonatal cots and additional morbidity 
and mortality.
Measuring the incidence of neonatal 
complications of COVID-19 accurately 
and comprehensively is therefore crit-
ical to provide optimal advice and care. 
Understanding rates of vertical and peri-
natal horizontal transmission is essen-
tial to inform newborn care following 
birth to an affected mother, where 
current UK practice—keeping mother 
and newborn together and encouraging 
breastfeeding—differs from countries 
affected earlier in the pandemic. Data 
describing the neonatal impact of 
maternal management of COVID-19 
are vital to inform maternity care and 
neonatal service delivery. Moreover, 
information describing both the severity 
of COVID-19 and current management 
is key to informing treatment, ideally 
in the context of randomised trials. 
Large, national, adaptive trials have 
been rapidly developed, including the 
Randomised Evaluations of COVID-19 
Therapy Trial ( www. recoverytrial. net), 
comparing multiple potential treat-
ments for COVID-19. Although this 
trial predominantly targets adults, preg-
nant women and children (including 
neonates) are eligible, and enrolment 
should be considered in severe disease.
Given the critical relevance of inci-
dence data, it is important to note that 
much currently available information 
comes from limited case series or single- 
centre studies rather than population- 
based surveillance, which is more robust, 
objective and less likely to be biased 
by local practices and protocols. Accu-
rate population- level incidence data are 
essential, and acquisition of such data 
requires active population surveillance; 
this differs from generally unrepresen-
tative data collected through registries 
that are unable to inform incidence or 
complication rates at population level. 
The British Paediatric Surveillance Unit 
(BPSU) has pioneered active surveil-
lance for rare diseases in the UK and 
internationally since 1985. The orange 
card system developed by the BPSU has 
been an exemplar for the development 
of national surveillance in other special-
ties (such as UK Obstetric Surveillance 
System (UKOSS)) and internationally. 
Crucially, BPSU contacts paediatricians 
and neonatologists across the UK and 
Ireland every month and asks them to 
report whether they have managed a 
case of any condition under active BPSU 
surveillance. A response is requested 
even if no cases were encountered; this 
ensures high case ascertainment with 
more than 90% of paediatrician and 
neonatologists responding to the BPSU 
every month. This methodology enables 
accurate estimation of regional and 
national incidence, clinical and outcome 
data in rare diseases in children.
A BPSU study on neonatal complica-
tions of COVID-19 has been developed 
to perform active surveillance to address 
key uncertainties related to COVID-19 
in neonates. Any neonate that meets the 
surveillance case definition (box 1) in the 
UK should be reported to the BPSU. For 
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the first time, the BPSU is asking for cases 
of neonatal complications of COVID-19 
to be reported weekly to capture more 
timely data to inform clinical care; this 
will be reviewed as the pandemic evolves 
(data collection form: online supple-
mentary file 1). For more complete case 
ascertainment, this BPSU surveillance 
will link with other related data sources, 
including ongoing UKOSS surveillance 
of COVID-19 in pregnancy for maternal 
cases, Mothers and Babies: Reducing Risk 
through Audits and Confidential Enqui-
ries across the UK (MBRRACE- UK), 
for neonatal deaths and stillbirths, and 
Public Health England (PHE), Health 
Protection Scotland, Public Health Wales 
and the Health and Social Care Public 
Health Agency in Northern Ireland. To 
limit reporting burden during a period 
of increased healthcare activity and to 
further ensure complete case ascertain-
ment, this BPSU surveillance will also 
link with routinely recorded neonatal 
and paediatric intensive care data held 
in the National Neonatal Research Data-
base (NNRD) and the Paediatric Inten-
sive Care Audit Network (PICANet). The 
resulting UK population- level incidence 
data will be used to inform clinical care, 
advice to pregnant women and service 
provision, and will be shared with global 
registries for international comparisons, 
further reducing reporting burden for 
clinicians.
The BPSU surveillance focuses on 
symptomatic cases that require hospital 
admission and the neonatal impact of 
maternal COVID-19. Similar surveillance 
of children older than 28 days of age who 
test positive for SARS- CoV-2 is being 
undertaken through PHE, and cases can 
be reported directly to  phe. paedcovid@ 
nhs. net. To better understand the vertical 
and horizontal transmission following 
SARS- CoV-2 infection in pregnancy, 
including asymptomatic transmission, the 
periCOVID study ( www. pericovid. com) 
has been established at St Georges Hospital 
in collaboration with PHE. This seeks to 
recruit pregnant women with COVID-19 
to collect antenatal, perinatal and post-
natal samples for viral and serological 
testing. Further initiatives are seeking to 
understand the impact of COVID-19 on 
neonatal services (https:// public. vtoxford. 
org/ covid- 19/).
Available data suggest that most 
infants and children with COVID-19 
develop mild to moderate illness only. 
However, there remains considerable 
uncertainty about the burden of disease 
in higher- risk groups, such as neonates, 
especially those born preterm, the wider 
impact of COVID-19 in pregnancy on 
neonatal outcomes and the influence 
of different models of postnatal care 
on neonatal disease. Active surveillance 
through established national systems 
such as the BPSU and UKOSS with very 
high population- based case ascertain-
ment is among the simplest, quickest and 
most efficient way to obtain the accurate 
population level incidence data and to 
determine true infection rates, clinical 
characteristics and outcomes, which are 
needed to inform optimal perinatal and 
neonatal care.
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Box 1 British Paediatric Surveillance Unit surveillance case definition for 
neonatal complications of COVID-19
Any baby or infant
1. That has a diagnosis of COVID-19 made on a sample taken before 29 days of age 
and receives inpatient care for COVID-19 (this includes postnatal ward, neonatal unit, 
paediatric inpatient wards and paediatric intensive care units) or
2. Where the mother had confirmed COVID-19 at the time of birth or suspected 
COVID-19 at the time of birth that has subsequently been confirmed, and the baby 
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